Inside the research
IQVIA Holdings Inc.
IQV Research profile · latest available data
Price overview
$270.37
▼ -4.65 (-1.7%)
| 52w hi | $275.02 |
|---|---|
| 52w lo | $156.66 |
| Vol | 1.10M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.43
| Short | +0.44 |
|---|---|
| Medium | +0.54 |
| Long | +0.20 |
computed 2026-09-27
Key fundamentals
IQVIA Holdings Inc.
Healthcare · Diagnostics & Research
| Market cap | $44.50B |
|---|---|
| Enterprise value | $58.81B |
| Trailing P/E | 33.67x |
| Forward P/E | 18.70x |
| EV / EBITDA | 19.29x |
| P / S (ttm) | 2.62x |
| Profit margin | 8.1% |
| Return on equity | 22.8% |
| Revenue growth | +8.7% |
| Earnings growth | -0.6% |
| Debt / equity | 257.98 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.16 | |
| Sector | +0.08 | |
| Technical | +0.34 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Risk Metrics
| Beta vs SPX | 1.00 |
|---|---|
| Corr SPX | 0.40 |
| Annual vol | 39.8% |
| Annual ret | +13.4% |
| Sharpe | 0.34 |
| Max DD | -43.1% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $228.60 |
|---|---|
| High / Low | $287.00 / $195.00 |
| Median | $223.00 |
| Analysts | 20 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 17 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-08 | Evercore ISI Group | → Outperform |
| 2026-03-09 | TD Cowen | → Buy |
| 2026-03-06 | Barclays | → Overweight |
| 2026-03-03 | RBC Capital | → Outperform |
| 2026-02-19 | Truist Securities | → Buy |
| 2026-02-06 | UBS | → Buy |
Officers & Board
| Founder | Dennis Gillings current |
|---|
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-28 | Earnings Release, Exhibits | read |
| 2026-06-11 | Material Agreement, Material Obligation… | read |
| 2026-06-04 | Other Material Event, Exhibits | read |
| 2026-06-03 | Other Material Event, Exhibits | read |
| 2026-05-07 | Other Material Event, Exhibits | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-04-23 | Officer / Director Change, Shareholder Vote… | read |
| 2026-02-05 | Earnings Release, Exhibits | read |
| 2025-12-09 | Material Agreement, Material Obligation… | read |
| 2025-11-05 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-10-28 | Earnings Release, Exhibits | read |
| 2025-09-02 | Officer / Director Change, Reg FD Disclosure… | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 96.3% |
| HHI | 4,413 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $1.45B | 7.51M |
| AQR Capital Management | $296.95M | 1.54M |
| Fidelity / FMR LLC | $234.31M | 1.21M |
| Millennium Management | $105.31M | 545.02K |
| Capital Research / Capital World | $99.29M | 513.86K |
| Citadel Advisors | $78.71M | 407.37K |
| Bridgewater Associates | $5.06M | 26.21K |
| T. Rowe Price Group | $67.88K | 351.28K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2013–2025 · 13 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $16.31B | +10.2% | |
| Operating income | $2.18B | +30.2% | |
| Net income | $1.36B | +16.1% | |
| Cash from ops | $2.15B | +14.0% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $274.90 | $274.90 | $269.43 | $270.37 | 1.10M |
| Sep 24 | $266.46 | $277.13 | $266.46 | $275.02 | 1.89M |
| Sep 23 | $270.66 | $277.40 | $267.42 | $267.86 | 1.12M |
| Sep 22 | $270.25 | $272.44 | $267.26 | $270.09 | 950.70K |
| Sep 21 | $266.76 | $270.86 | $265.25 | $269.88 | 1.93M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →